Patient understanding of pharmacogenomic test results in clinical care.

[1]  A. Pittenger,et al.  Development and Validation of the Minnesota Assessment of Pharmacogenomic Literacy (MAPL) , 2022, Journal of personalized medicine.

[2]  B. Canady,et al.  Overconfidence in Managing Health Concerns: The Dunning–Kruger Effect and Health Literacy , 2022, Journal of Clinical Psychology in Medical Settings.

[3]  Yee Ming Lee,et al.  Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update , 2022, Clinical pharmacology and therapeutics.

[4]  S. Kazi,et al.  Pharmacogenomic Clinical Decision Support: A Review, How‐to Guide, and Future Vision , 2021, Clinical pharmacology and therapeutics.

[5]  Peter H. Schwartz,et al.  Incorporating Biobank Consent into a Healthcare Setting: Challenges for Patient Understanding , 2020, AJOB empirical bioethics.

[6]  I. Patel,et al.  Clinical Application and Educational Training for Pharmacogenomics , 2020, Pharmacy.

[7]  Julia M. Barbarino,et al.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing , 2020, Clinical pharmacology and therapeutics.

[8]  B. Rasmussen,et al.  Teach-back: A systematic review of implementation and impacts , 2020, PloS one.

[9]  R. Woosley,et al.  Identification of populations likely to benefit from pharmacogenomic testing , 2020, Pharmacogenetics and genomics.

[10]  Sophie Veilleux,et al.  Patient and Health Care Provider Needs and Preferences in Understanding Pharmacogenomic and Genomic Testing: A Meta-Data Analysis , 2020, Qualitative health research.

[11]  S. Haga,et al.  Patient characteristics, experiences and perceived value of pharmacogenetic testing from a single testing laboratory. , 2019, Pharmacogenomics.

[12]  D. Oslin,et al.  Projected Prevalence of Actionable Pharmacogenetic Variants and Level A Drugs Prescribed Among US Veterans Health Administration Pharmacy Users , 2019, JAMA network open.

[13]  A. Leasure,et al.  Use and Effectiveness of the Teach-Back Method in Patient Education and Health Outcomes. , 2019, Federal practitioner : for the health care professionals of the VA, DoD, and PHS.

[14]  K. Weinfurt,et al.  Exploring Understanding of “Understanding”: The Paradigm Case of Biobank Consent Comprehension , 2019, The American journal of bioethics : AJOB.

[15]  Pedro J. Caraballo,et al.  Pharmacogenomic clinical decision support design and multi-site process outcomes analysis in the eMERGE Network , 2019, J. Am. Medical Informatics Assoc..

[16]  K. Maloney,et al.  Parkinson’s Disease: Patients’ Knowledge, Attitudes, and Interest in Genetic Counseling , 2018, Journal of Genetic Counseling.

[17]  A. Barratt,et al.  Psychosocial Impact of a Positive Gene Result for Asymptomatic Relatives at Risk of Hypertrophic Cardiomyopathy , 2018, Journal of Genetic Counseling.

[18]  P. Hulick,et al.  Patient perspectives following pharmacogenomics results disclosure in an integrated health system. , 2018, Pharmacogenomics.

[19]  R. Hussein,et al.  Impact of a pharmacist-provided information booklet on knowledge and attitudes towards oral contraception among Jordanian women: an interventional study , 2017, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[20]  K. Helzlsouer,et al.  Updating the landscape of direct-to-consumer pharmacogenomic testing , 2017, Pharmacogenomics and personalized medicine.

[21]  K. Sangkuhl,et al.  Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update , 2017, Clinical pharmacology and therapeutics.

[22]  John J. Connolly,et al.  Healthcare provider education to support integration of pharmacogenomics in practice: the eMERGE Network experience. , 2017, Pharmacogenomics.

[23]  Yee Ming Lee,et al.  Assessment of patient perceptions of genomic testing to inform pharmacogenomic implementation , 2017, Pharmacogenetics and genomics.

[24]  Carolyn R Rohrer Vitek,et al.  Participant perceived understanding and perspectives toward pharmacogenomics: Mayo Clinic Right Drug, Right Dose, Right Time (RIGHT) Protocol , 2016, Genetics in Medicine.

[25]  G. Ginsburg,et al.  Patient experiences with pharmacogenetic testing in a primary care setting. , 2016, Pharmacogenomics.

[26]  M. D. De Marinis,et al.  Written Information Improves Patient Knowledge About Implanted Ports. , 2016, Clinical journal of oncology nursing.

[27]  P. Butow,et al.  Public preferences for communicating personal genomic risk information: a focus group study , 2015, Health expectations : an international journal of public participation in health care and health policy.

[28]  S. Gallagher,et al.  Critical Neuroscience and Socially Extended Minds , 2015 .

[29]  Harlan M Krumholz,et al.  Quality of discharge practices and patient understanding at an academic medical center. , 2013, JAMA internal medicine.

[30]  B. Peshkin,et al.  Translational genomic research: protocol development and initial outcomes following SNP testing for colon cancer risk , 2013, Translational behavioral medicine.

[31]  Peter H. Schwartz,et al.  Patient understanding of benefits, risks, and alternatives to screening colonoscopy. , 2013, Family medicine.

[32]  W Burke,et al.  Primary care physicians' knowledge of and experience with pharmacogenetic testing , 2012, Clinical genetics.

[33]  A. Harralson,et al.  The current and future state of pharmacogenomics medical education in the USA. , 2012, Pharmacogenomics.

[34]  Kirsten G. Engel,et al.  Patient understanding of emergency department discharge instructions: where are knowledge deficits greatest? , 2012, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[35]  Julianne M. O’Daniel,et al.  Public perspectives about pharmacogenetic testing and managing ancillary findings. , 2012, Genetic testing and molecular biomarkers.

[36]  R. Adepu,et al.  Development and Evaluation of Patient Information Leaflets (PIL) Usefulness , 2012, Indian journal of pharmaceutical sciences.

[37]  Julianne M. O’Daniel,et al.  Survey of U.S. Public Attitudes Towards Pharmacogenetic Testing , 2011, The Pharmacogenomics Journal.

[38]  A. Harralson,et al.  Pharmacogenomics instruction in US and Canadian medical schools: implications for personalized medicine. , 2010, Pharmacogenomics.

[39]  R. Klitzman.  Misunderstandings Concerning Genetics Among Patients Confronting Genetic Disease , 2010, Journal of Genetic Counseling.

[40]  P. Aslani,et al.  Impact of Vietnamese written and verbal medicine information on Vietnamese-speaking Australians' knowledge and satisfaction. , 2007, British journal of clinical pharmacology.

[41]  Marie Leiner,et al.  Communicating genetic information: a difficult challenge for future pediatricians , 2007, BMC medical education.

[42]  E. Boyko,et al.  Brief questions to identify patients with inadequate health literacy. , 2004, Family medicine.

[43]  Diane G. Schwartz,et al.  Barriers, Facilitators, and Solutions to Optimal Patient Portal and Personal Health Record Use: A Systematic Review of the Literature , 2017, AMIA.

[44]  J. Brockmöller,et al.  Patients' and physicians' perspectives on pharmacogenetic testing. , 2006, Pharmacogenomics.

[45]  J. Hill,et al.  The development and evaluation of a drug information leaflet for patients with rheumatoid arthritis. , 2003, Rheumatology.